TORCH

Towards a Revolution in COPD Health

Patient / Population Intervention / Exposition Vergleich Endpunkt

In 6,112 patients with moderate-to-severe COPD, salmeterol-fluticasone reduced 3-year all-cause mortality only borderline-significantly compared with placebo.

6.112

Design

Multicentre RCT

Endpunkt

All-cause mortality at 3 years

Relevanz

Ergebnis12.6% vs 15.2% (HR 0.825; p=0.052). Exacerbations reduced 25%. Pneumonia 19.6% vs 12.3%.

Calverley PMA, et al. N Engl J Med. 2007;356(8):775-789. 10.1056/NEJMoa063070

Diskussion & Kritik

First large mortality trial in COPD; established LABA/ICS for exacerbation reduction and surfaced the ICS-pneumonia signal that persists in later trials.